|
시장보고서
상품코드
2075350
헤모글로빈이상증 시장 : 검사 유형별, 적응증별, 최종사용자별, 지역별Hemoglobinopathy Market, by Test Type, by Indication, by End User, and by Region |
||||||
헤모글로빈이상증 시장은 2026년에 7억 5,800만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 11억 4,730만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 6.1%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 7억 5,800만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2033년) | 6.10% | 예측 금액(2033년) | 11억 4,730만 달러 |
헤모글로빈이상증이란 헤모글로빈 분자의 생성 또는 구조에 이상이 발생하는 유전성 질환군을 말합니다. 헤모글로빈이상증은 주로 적혈구에 영향을 미치는 일련의 유전성 혈액 질환을 가리키는 의학 용어입니다. 낫형 적혈구증(SCD)은 적혈구를 손상시키고 변형시키는 비정상적인 헤모글로빈에 의해 유발되는 혈액 질환 중 하나입니다. 주요 분류로는 헤모글로빈 유전자의 변이로 인해 발생하는 구조 이상형 헤모글로빈 변이체와, 정상적인 헤모글로빈 분자의 변질로 인해 발생하는 살라세미아의 두 가지 그룹이 있습니다. 주요 구조 이상형 헤모글로빈 변이체로는 HbS, HbE, HbC가 있습니다. 주요 살라세미아의 유형로는 α-살라세미아와 베타-살라세미아가 있습니다. 헤모글로빈 단백질의 이상을 유발하는 일부 질환은 그 생성에도 영향을 미치기 때문에 이 두 질환이 중복되는 경우가 있습니다.
일부 헤모글로빈 변이체는 병태나 빈혈을 유발하지 않기 때문에 헤모글로빈이상증으로 분류되지 않는 경우가 많습니다. 이 질환의 일반적인 증상으로는 심한 통증, 호흡 곤란, 비장 비대, 그리고 소아의 성장 장애 등이 있습니다. 이는 적혈구 내에 변이형 헤모글로빈이 존재함으로써 유발되는 모든 질환군을 지칭하는 경우가 있습니다.
시장 역학
시장의 주요 기업이 제품 포트폴리오를 확대하기 위해 제휴를 맺는 등, 유기적 성장 전략의 채택이 증가함에 따라 예측 기간 중 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어 2022년 6월, 미국의 상장 임상 단계 유전자 편집 기업인 Precision BioSciences사와 제약 기업 노바티스 AG는 혈액 질환에 대한 새로운 유전자 치료법을 개발하기 위해 제휴를 맺었다고 발표했습니다.
이 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 시장 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략 등에 관한 중요 인사이트도 제공하고 있습니다.
- 세계의 헤모글로빈이상증 시장의 주요 기업 개요을 각종 지표(기업 개요, 제품 포트폴리오, 주요 동향, 재무 실적, 전략 등)를 바탕으로 수록하고 있습니다.
- 이 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 기술 업데이트, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- '세계의 헤모글로빈이상증 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 전 세계 헤모글로빈이상증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 헤모글로빈이상증 시장 : 검사 유형별(2021-2033년)
제5장 세계의 헤모글로빈이상증 시장 : 적응증별(2021-2033년)
제6장 세계의 헤모글로빈이상증 시장 : 최종사용자별(2021-2033년)
제7장 세계의 헤모글로빈이상증 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 섹션
KSA 26.07.08Hemoglobinopathy Market is estimated to be valued at USD 758.0 Mn in 2026 and is expected to reach USD 1,147.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 758.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.10% | 2033 Value Projection: | USD 1,147.3 Mn |
Hemoglobinopathy are a group of disorders that are inherited, in which there is abnormal production or structure of the hemoglobin molecule. Hemoglobinopathy is the medical term for a group of inherited blood disorders and diseases that primarily affect red blood cells. Sickle cell disease (SCD) is one such blood disorder caused by the abnormal hemoglobin that damages and deforms red blood cells. There are two main groups, which are abnormal structural hemoglobin variants caused by mutations in the hemoglobin genes, and the thalassemias, which are caused by an alteration in normal hemoglobin molecules. The main structural hemoglobin variants are HbS, HbE and HbC. The main types of thalassemia are alpha-thalassemia and beta thalassemia. The two conditions may overlap because some conditions, which cause abnormalities in hemoglobin proteins also affect their production.
Some hemoglobin variants do not cause pathology or anemia, and thus are often not classed as hemoglobinopathies. Common symptoms of the condition include, severe pain, shortness of breath, enlarged spleen, and growth problems in children. It can be any group of disorders caused by the presence of variant hemoglobin in the red blood cells.
Market Dynamics
Increasing adoption of organic growth strategies, such as partnerships by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in June 2022, Precision BioSciences, a publicly traded American clinical stage gene editing company, and Novartis AG, a pharmaceutical corporation, announced that they have entered into a partnership to develop new gene therapy for blood disorders.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hemoglobinopathy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Anamol Laboratories Pvt. Ltd., Bio-Rad Laboratories, Inc., PerkinElmer Inc., Zentech, Sebia, Sysmex Europe SE, Nanjing Poclight Biotechnology Co., Ltd, Abbott, Danaher, ReachBio LLC, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Nexcelom Bioscience LLC., NIHON KOHDEN CORPORATION, Siemens Healthcare GmbH, CRISPR Therapeutics.
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global hemoglobinopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemoglobinopathy market
Detailed Segmentation:
- Global Hemoglobinopathy Market, By Test Type (Revenue, USD Mn, 2021 - 2033)
- Routine Red Blood Cell (RBC) count
- Genetic Testing
- Hemoglobin by high performance liquid chromatography
- Hemoglobin isoelectric focusing ( Hb IEF)
- Hemoglobin electrophoresis (Hb ELP)
- Hemoglobin solubility test
- Global Hemoglobinopathy Market, By Indication (Revenue, USD Mn, 2021 - 2033)
- Sickle Cell Disease
- Beta Thalassemia
- Alpha Thalassemia
- Global Hemoglobinopathy Market, By End User (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Diagnostic Laboratories
- Clinics
- Global Hemoglobinopathy Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- Company Profiles
- Anamol Laboratories Pvt. Ltd.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bio-Rad Laboratories, Inc.
- PerkinElmer Inc.
- Zentech
- Sebia
- Sysmex Europe SE
- Nanjing Poclight Biotechnology Co., Ltd
- Abbott
- Danaher
- ReachBio LLC
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Nexcelom Bioscience LLC.
- NIHON KOHDEN CORPORATION
- Siemens Healthcare GmbH.
- CRISPR Therapeutics
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Test Type
- Market Snapshot, By Indication
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product Launch
- Technological Advancements
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions
4. Global Hemoglobinopathy Market, By Test Type, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Routine Red Blood Cell (RBC) count
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Genetic Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Hemoglobin by high performance liquid chromatography
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Hemoglobin isoelectric focusing ( Hb IEF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Hemoglobin electrophoresis (Hb ELP)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Hemoglobin solubility test
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Hemoglobinopathy Market, By Indication, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Sickle Cell Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Beta Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Alpha Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Hemoglobinopathy Market, By End User, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segments Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
7. Global Hemoglobinopathy Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Anamol Laboratories Pvt. Ltd.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bio-Rad Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PerkinElmer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zentech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sebia
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sysmex Europe SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Nanjing Poclight Biotechnology Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Danaher
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ReachBio LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Nexcelom Bioscience LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NIHON KOHDEN CORPORATION
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Siemens Healthcare GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CRISPR Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
